Patents Assigned to TACT IP, LLC
-
Patent number: 9808523Abstract: A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included.Type: GrantFiled: November 8, 2014Date of Patent: November 7, 2017Assignee: TACT IP LLCInventor: Edward Lewis Tobinick
-
Patent number: 8900583Abstract: A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included.Type: GrantFiled: October 31, 2011Date of Patent: December 2, 2014Assignee: TACT IP LLCInventor: Edward Lewis Tobinick
-
Publication number: 20130224197Abstract: A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included.Type: ApplicationFiled: October 31, 2011Publication date: August 29, 2013Applicant: TACT IP LLCInventor: Edward Lewis Tobinick
-
Publication number: 20130022540Abstract: A method for delivering a biologic to a human, comprising administering said biologic parenterally into the perispina! space of said human without direct intrathecal injection and positioning said human in a Trendelenburg position.Type: ApplicationFiled: July 23, 2012Publication date: January 24, 2013Applicant: TACT IP LLCInventor: Edward Lewis Tobinick
-
Patent number: 8349323Abstract: A method for delivering a biologic pharmaceutical, comprising: administering an effective amount of a biologic pharmaceutical to a patient in need thereof by perispinal injection, without direct intrathecal or direct epidural injection.Type: GrantFiled: February 20, 2012Date of Patent: January 8, 2013Assignee: Tact IP, LLCInventor: Edward L. Tobinick
-
Publication number: 20090130019Abstract: This application concerns novel methods which enable or improve the ability of molecules, particularly large molecules, to cross the blood-brain barrier, the blood-eye barrier, and/or the blood-nerve barrier and therefore be of improved diagnostic and/or therapeutic use in humans and other mammals. These methods involve perispinal administration of imaging agents without direct intrathecal injection. Perispinal administration is defined as administration of the molecule into the anatomic area within 10 cm of the spine. Perispinal administration results in absorption of the imaging agent into the vertebral venous system.Type: ApplicationFiled: November 21, 2007Publication date: May 21, 2009Applicant: TACT IP, LLCInventor: Edward Lewis Tobinick
-
Publication number: 20070196375Abstract: A method for delivering a biologic to a human with Alzheimer's-related dementia, comprising administering the biologic parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human's head below the horizontal. The method further includes delivering a TNF antagonist to the brain of a human for treating mild cognitive impairment, Alzheimer's related dementia, or vascular dementia, comprising administering the TNF antagonist golimumab parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human in a Trendelenburg position, for delivery of the golimumab to the brain via the human's vertebral venous system.Type: ApplicationFiled: November 17, 2006Publication date: August 23, 2007Applicant: Tact IP, LLCInventor: Edward Tobinick
-
Patent number: 7214658Abstract: The present invention provides specific methods of using and administering etanercept to improve cognitive function in a human, for both the treatment and prevention of cognitive impairment, or, alternatively, to enhance cognitive function including Alzheimer's Disease, Idiopathic Dementia, and Traumatic Brain Injury. The methods of the present invention include the perispinal administration of etanercept. For the purposes of this patent “perispinal” is to be considered as referring to “perispinal extrathecal;” therefore direct intrathecal administration is excluded. Perispinal administration leads to enhanced delivery of etanercept to the brain in a therapeutically effective amount, via the vertebral venous system and/or the cerebrospinal fluid. Delivery of etanercept to the brain utilizing the methods of the present invention includes the use of the vertebral venous system to deliver etanercept to the brain via retrograde venous flow.Type: GrantFiled: December 18, 2004Date of Patent: May 8, 2007Assignee: Tact IP, LLCInventor: Edward L. Tobinick
-
Patent number: 6982089Abstract: Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additonally, intranasal administration is discussed as a method to provide therapeutic benefit.Type: GrantFiled: October 9, 2002Date of Patent: January 3, 2006Assignee: TACT IP, LLCInventor: Edward Lewis Tobinick
-
Patent number: RE45976Abstract: A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly. Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.Type: GrantFiled: December 26, 2008Date of Patent: April 19, 2016Assignee: TACT IP, LLCInventor: Edward L. Tobinick